Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK4381562 |
Synonyms | |
Therapy Description |
GSK4381562 (SRF813) is a monoclonal antibody targeting CD112R (PVRIG), which potentially increases NK cell activation and inhibits tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 4548). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK4381562 | GSK-4381562|GSK 4381562|SRF813|SRF-813|SRF 813 | GSK4381562 (SRF813) is a monoclonal antibody targeting CD112R (PVRIG), which potentially increases NK cell activation and inhibits tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 4548). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |